Avinash Desai
Al-Ameen Medical College(IN)Actinium Pharmaceuticals (United States)(US)
Publications by Year
Research Areas
Multiple Myeloma Research and Treatments, Acute Myeloid Leukemia Research, Protein Degradation and Inhibitors, Chronic Myeloid Leukemia Treatments, Peptidase Inhibition and Analysis
Most-Cited Works
- → Bortezomib-Based Versus Nonbortezomib-Based Induction Treatment Before Autologous Stem-Cell Transplantation in Patients With Previously Untreated Multiple Myeloma: A Meta-Analysis of Phase III Randomized, Controlled Trials(2013)250 cited
- → Use of a claims database to characterize and estimate the incidence rate for Castleman disease(2014)163 cited
- → Analysis of Real-World Data on Overall Survival in Multiple Myeloma Patients With ≥3 Prior Lines of Therapy Including a Proteasome Inhibitor (PI) and an Immunomodulatory Drug (IMiD), or Double Refractory to a PI and an IMiD(2016)139 cited
- A phase I/IIA trial of continuous five-day infusion of squalamine lactate (MSI-1256F) plus carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.(2003)
- → Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy(2014)50 cited
- → A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma(2017)